Nicholas Turner, MD, PhD
The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival (OS) compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer who received prior endocrine therapy, according to Pfizer, the developer of the CDK4/6 inhibitor.
OS was a secondary endpoint for the PALOMA-3 trial. The primary endpoint of progression-free survival (PFS) was previously reported and led to FDA approval for palbociclib plus fulvestrant for pretreated women with HR+/HER2- metastatic breast cancer. In findings published in The Lancet Oncology,1
the median PFS was 9.5 months with palbociclib/fulvestrant compared with 4.6 months for fulvestrant alone (HR, 0.46; 95% CI, 0.36-0.59; P
... to read the full story